Skip to Content

WATSON 3209 (Rivastigmine 3 mg)

Pill imprint WATSON 3209 has been identified as Rivastigmine tartrate 3 mg.

Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substance Act (CSA).

Rivastigmine tartrate 3 mg WATSON 3209
Rivastigmine tartrate 3 mg WATSON 3209
Discount Card Promo
Rivastigmine tartrate
Imprint:
WATSON 3209
Strength:
3 mg
Color:
Yellow
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Cholinesterase inhibitors
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Manufacturer:
Watson Pharmaceuticals
National Drug Code (NDC):
00591-3209
Inactive Ingredients:
silicon dioxide colloidal
hypromellose
magnesium stearate
microcrystalline cellulose
gelatin
titanium dioxide
ferric oxide yellow
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
63739-0577 McKesson Packaging Services

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide